Antoine N Saliba (Antoine Saliba)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 31

Top Topics

Acute Lymphoblastic Leukemia

Newly Diagnosed

Allogeneic Hematopoietic Stem Cell Transplantation

Top Venues

American journal of hematology

Blood cancer journal

British journal of haematology

This page only lists publications with an associated author ORCID identifier.

Publications

Isla M Johnson, Omer Karrar, Masooma Rana, Moazah Iftikhar, Sunny Chen, Kristen McCullough, Antoine N Saliba, Aref A Al-Kali, Hassan B Alkhateeb, Kebede Begna, Mark Litzow, William J Hogan, Mithun Vinod Shah, Mrinal M Patnaik, Animesh D Pardanani, Joerg Hermann, Ayalew Tefferi, Naseema Gangat
Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents. British journal of haematology 204 (4) (2024)
Talha Badar, Ahmad Nanaa, Ehab Atallah, Rory M Shallis, Sacchi de Camargo Correia Guilherme, Aaron D Goldberg, Antoine N Saliba, Anand Ashwin Patel, Jan Philipp Bewersdorf, Adam S DuVall, Danielle Bradshaw, Yasmin M Abaza, Guru Subramanian Guru Murthy, Neil Palmisiano, Amer M Zeidan, Vamsi K Kota, Mark R Litzow
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood cancer journal 14 (1) (2024)
Isla M Johnson, Omer Karrar, Masooma Rana, Moazah Iftikhar, Sunny Chen, Kristen McCullough, Antoine N Saliba, Aref A Al-Kali, Hassan B Alkhateeb, Kebede Begna, Mark Litzow, William J Hogan, Mithun Vinod Shah, Mrinal M Patnaik, Animesh D Pardanani, Joerg Hermann, Ayalew Tefferi, Naseema Gangat
Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents. British journal of haematology 204 (4) (2024)
Talha Badar, Ahmad Nanaa, Ehab Atallah, Rory M Shallis, Sacchi de Camargo Correia Guilherme, Aaron D Goldberg, Antoine N Saliba, Anand Ashwin Patel, Jan Philipp Bewersdorf, Adam S DuVall, Danielle Bradshaw, Yasmin M Abaza, Guru Subramanian Guru Murthy, Neil Palmisiano, Amer M Zeidan, Vamsi K Kota, Mark R Litzow
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood cancer journal 14 (1) (2024)
Talha Badar, Ahmad Nanaa, Ehab Atallah, Rory M Shallis, Sacchi de Camargo Correia Guilherme, Aaron D Goldberg, Antoine N Saliba, Anand Ashwin Patel, Jan Philipp Bewersdorf, Adam S DuVall, Danielle Bradshaw, Yasmin M Abaza, Guru Subramanian Guru Murthy, Neil Palmisiano, Amer M Zeidan, Vamsi K Kota, Mark R Litzow
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood cancer journal 14 (1) (2024)
Talha Badar, Ahmad Nanaa, Ehab Atallah, Rory M Shallis, Sacchi de Camargo Correia Guilherme, Aaron D Goldberg, Antoine N Saliba, Anand Ashwin Patel, Jan Philipp Bewersdorf, Adam S DuVall, Danielle Bradshaw, Yasmin M Abaza, Guru Subramanian Guru Murthy, Neil Palmisiano, Amer M Zeidan, Vamsi K Kota, Mark R Litzow
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood cancer journal 14 (1) (2024)
Talha Badar, Ahmad Nanaa, Ehab Atallah, Rory M Shallis, Sacchi de Camargo Correia Guilherme, Aaron D Goldberg, Antoine N Saliba, Anand Ashwin Patel, Jan Philipp Bewersdorf, Adam S DuVall, Danielle Bradshaw, Yasmin M Abaza, Guru Subramanian Guru Murthy, Neil Palmisiano, Amer M Zeidan, Vamsi K Kota, Mark R Litzow
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood cancer journal 14 (1) (2024)
Talha Badar, Ahmad Nanaa, Ehab Atallah, Rory M Shallis, Sacchi de Camargo Correia Guilherme, Aaron D Goldberg, Antoine N Saliba, Anand Ashwin Patel, Jan Philipp Bewersdorf, Adam S DuVall, Danielle Bradshaw, Yasmin M Abaza, Guru Subramanian Guru Murthy, Neil Palmisiano, Amer M Zeidan, Vamsi K Kota, Mark R Litzow
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood cancer journal 14 (1) (2024)
Talha Badar, Ahmad Nanaa, Ehab Atallah, Rory M Shallis, Sacchi de Camargo Correia Guilherme, Aaron D Goldberg, Antoine N Saliba, Anand Ashwin Patel, Jan Philipp Bewersdorf, Adam S DuVall, Danielle Bradshaw, Yasmin M Abaza, Guru Subramanian Guru Murthy, Neil Palmisiano, Amer M Zeidan, Vamsi K Kota, Mark R Litzow
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood cancer journal 14 (1) (2024)
Isla M Johnson, Omer Karrar, Masooma Rana, Moazah Iftikhar, Sunny Chen, Kristen McCullough, Antoine N Saliba, Aref A Al-Kali, Hassan B Alkhateeb, Kebede Begna, Mark Litzow, William J Hogan, Mithun Vinod Shah, Mrinal M Patnaik, Animesh D Pardanani, Joerg Hermann, Ayalew Tefferi, Naseema Gangat
Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents. British journal of haematology (2024)
Omer S Karrar, Maymona Abdelmagid, Masooma Rana, Moazah Iftikhar, McCullough Kristen, Aref A Al-Kali, Hassan B Alkhateeb, Kebede H Begna, Michelle A Elliott, Abhishek A Mangaonkar, Antoine N Saliba, Mehrdad Hefazi, Mark R Litzow, William Hogan, Mithun Vinod Shah, Mirinal S Patnaik, Animesh D Pardanani, Talha Badar, Hemant S Murthy, James Foran, Jeanne Palmer, Lisa Sproat, Nandita Khera, Cecilia Y Arana Yi, Ayalew Tefferi, Naseema Gangat
Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival. American journal of hematology 99 (2) (2023)
Naseema Gangat, Omer S Karrar, Moazah Iftikhar, McCullough Kristen, Isla M Johnson, Maymona Abdelmagid, Mostafa Abdallah, Aref A Al-Kali, Hassan B Alkhateeb, Kebede H Begna, Abhishek A Mangaonkar, Antoine N Saliba, Mehrdad Hefazi, Mark R Litzow, William Hogan, Mithun Vinod Shah, Mirinal S Patnaik, Animesh D Pardanani, Talha Badar, Hemant S Murthy, James Foran, Jeanne Palmer, Lisa Sproat, Nandita Khera, Cecilia Y Arana Yi, Ayalew Tefferi
Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients. American journal of hematology (2023)
Omer S Karrar, Maymona Abdelmagid, Masooma Rana, Moazah Iftikhar, McCullough Kristen, Aref A Al-Kali, Hassan B Alkhateeb, Kebede H Begna, Michelle A Elliott, Abhishek A Mangaonkar, Antoine N Saliba, Mehrdad Hefazi, Mark R Litzow, William Hogan, Mithun Vinod Shah, Mirinal S Patnaik, Animesh D Pardanani, Talha Badar, Hemant S Murthy, James Foran, Jeanne Palmer, Lisa Sproat, Nandita Khera, Cecilia Y Arana Yi, Ayalew Tefferi, Naseema Gangat
Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival. American journal of hematology 99 (2) (2023)
Naseema Gangat, Mostafa Abdallah, Natasha Szuber, Antoine N Saliba, Hassan Alkhateeb, Aref A Al-Kali, Kebede H Begna, Animesh D Pardanani, Ayalew Tefferi
Sodium-glucose co-transporter-2 inhibitor use and JAK2 unmutated erythrocytosis in 100 consecutive cases. American journal of hematology (2023)
Omer S Karrar, Maymona Abdelmagid, Masooma Rana, Moazah Iftikhar, McCullough Kristen, Aref A Al-Kali, Hassan B Alkhateeb, Kebede H Begna, Michelle A Elliott, Abhishek A Mangaonkar, Antoine N Saliba, Mehrdad Hefazi, Mark R Litzow, William Hogan, Mithun Vinod Shah, Mirinal S Patnaik, Animesh D Pardanani, Talha Badar, Hemant S Murthy, James Foran, Jeanne Palmer, Lisa Sproat, Nandita Khera, Cecilia Y Arana Yi, Ayalew Tefferi, Naseema Gangat
Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival. American journal of hematology (2023)
Antoine N Saliba, Khaled M Musallam, Ali T Taher
How I Treat Non-Transfusion-Dependent β-Thalassemia. Blood (2023)
Omer S Karrar, Maymona Abdelmagid, Masooma Rana, Moazah Iftikhar, McCullough Kristen, Aref A Al-Kali, Hassan B Alkhateeb, Kebede H Begna, Michelle A Elliott, Abhishek A Mangaonkar, Antoine N Saliba, Mehrdad Hefazi, Mark R Litzow, William Hogan, Mithun Vinod Shah, Mirinal S Patnaik, Animesh D Pardanani, Talha Badar, Hemant S Murthy, James Foran, Jeanne Palmer, Lisa Sproat, Nandita Khera, Cecilia Y Arana Yi, Ayalew Tefferi, Naseema Gangat
Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival. American journal of hematology 99 (2) (2023)
Antoine N Saliba, Robin Foà
Minimal residual disease in Philadelphia-positive acute lymphoblastic leukemia: Maximizing the clinical yield of testing. American journal of hematology (2023)
Antoine N Saliba, Robin Foà
The evolution of frontline therapy for adult Philadelphia-positive acute lymphoblastic leukemia: Giant strides and ongoing challenges. American journal of hematology (2022)
Antoine N Saliba, Robin Foà
The evolution of frontline therapy for adult Philadelphia-positive acute lymphoblastic leukemia: giant strides and ongoing challenges. American journal of hematology (2022)
Antoine N Saliba, Scott H Kaufmann, Eytan M Stein, Prapti Arvind Patel, Maria R Baer, Wendy Stock, Michael W Deininger, William Blum, Gary J Schiller, Rebecca L Olin, Mark R Litzow, Tara L Lin, Brian John Ball, Michael Boyiadzis, Jennifer Dunlap, Olatoyosi Odenike, Martha L Arellano, Alison R Walker, Vu H Duong, Tibor J Kovacsovics, Robert H Collins, Abigail B Shoben, Nyla A Heerema, Matthew C Foster, Kevin L Peterson, Paula A Schneider, Molly Martycz, Theophilus Gana, Leonard Rosenberg, Sonja Marcus, Ashley O Yocum, Timothy L Chen, Mona Stefanos, Alice S Mims, Uma Borate, Amy Burd, Brian J Druker, Ross L Levine, John C Byrd, James M Foran
Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates. Blood advances (2022)
Antoine N Saliba, Robin Foà
The evolution of frontline therapy for adult Philadelphia-positive acute lymphoblastic leukemia: Giant strides and ongoing challenges. American journal of hematology 98 (3) (2022)
Talha Badar, Ehab Atallah, Rory M Shallis, Aaron D Goldberg, Anand Ashwin Patel, Yasmin Abaza, Jan Philipp Bewersdorf, Antoine N Saliba, Guilherme Sacchi De Camargo Correia, Guru Subramanian Guru Murthy, Adam Duvall, Madelyn Burkart, Maximilian Stahl, Yuanhang Liu, Shira Dinner, Neil Palmisiano, Mark R Litzow, James M Foran
Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival. American journal of hematology 97 (7) (2022)
Antoine N Saliba, Robin Foà
The evolution of frontline therapy for adult Philadelphia-positive acute lymphoblastic leukemia: Giant strides and ongoing challenges. American journal of hematology 98 (3) (2022)
Antoine N Saliba, Robin Foà
The evolution of frontline therapy for adult Philadelphia-positive acute lymphoblastic leukemia: Giant strides and ongoing challenges. American journal of hematology 98 (3) (2022)
Antoine N Saliba, Robin Foà
The evolution of frontline therapy for adult Philadelphia-positive acute lymphoblastic leukemia: Giant strides and ongoing challenges. American journal of hematology 98 (3) (2022)
Antoine N Saliba, Mark R Litzow, Naseema Gangat, Aref Al-Kali, James M Foran, William J Hogan, Jeanne M Palmer, Abhishek A Mangaonkar, Ayalew Tefferi, Mirinal S Patnaik
Outcomes of venetoclax-based therapy in chronic phase and blast transformed chronic myelomonocytic leukemia. American journal of hematology 96 (11) (2021)
Antoine N Saliba, Zhuoer Xie, Alexandra S Higgins, Xavier A Andrade-Gonzalez, Harry E Fuentes-Bayne, Paul Joseph Hampel, Lionel A Kankeu Fonkoua, Daniel S Childs, Sagar Rakshit, Evandro D Bezerra, Anuhya Kommalapati, Yanyan Lou, Candido E Rivera, Katharine A Price, Ashish Chintakuntlawar, Yiyi Yan, Anna J Schwecke, Matthew S Block, Uma Thanarajasingam, Gita Thanarajasingam, Alexandra P Wolanskyj-Spinner, Ariela L Marshall, Lisa A Kottschade, Ronald S Go, Aref Al-Kali
Immune-related hematologic adverse events in the context of immune checkpoint inhibitor therapy. American journal of hematology 96 (10) (2021)
Antoine N Saliba, Ali T Taher
The Lebanese healthcare sector: The point of exsanguination. American journal of hematology 96 (11) (2021)
Clifford M Csizmar, Antoine N Saliba, Elizabeth M Swisher, Scott H Kaufmann
PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword. Cancers 13 (24) (2021)
Antoine N Saliba, Alejandro Ferrer, Naseema Gangat, Rajiv K Pruthi, Ayalew Tefferi, Alexandra S Higgins, Evandro D Bezerra, Alessia Buglioni, Mohamed E Salama, Eric W Klee, Filippo Pinto E Vairo, Abhishek A Mangaonkar, Julie Majerus, Dong Chen, Mrinal M Patnaik
Aetiology and outcomes of secondary myelofibrosis occurring in the context of inherited platelet disorders: A single institutional study of four patients. British journal of haematology 190 (5) (2020)